Tigermed Directors Probed by CSRC Over Shareholding Disclosures

Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.

Hangzhou Tigermed Consulting has disclosed that two of its directors and controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, are under investigation by the China Securities Regulatory Commission for suspected violations related to information disclosure on changes in the company’s shareholding. Both executives have said they will cooperate fully with regulators and comply with disclosure obligations as required under Chinese securities laws.

The board emphasized that the group’s business operations remain normal and that the regulatory probe is not expected to affect day-to-day activities, while pledging to update shareholders and the market as the situation develops. The company also urged shareholders and potential investors to exercise caution when trading its shares, underscoring the potential for short-term uncertainty around governance and regulatory risk despite assurances on operational continuity.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a China-based company listed in Hong Kong that operates in the clinical research and pharmaceutical services sector. The group provides outsourced clinical trial and related consulting services to biopharmaceutical companies, positioning itself as a key player in the contract research organization market serving healthcare and life sciences clients.

Average Trading Volume: 1,650,109

Technical Sentiment Signal: Sell

Current Market Cap: HK$44.25B

For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.